作者: Annemarie Ledeboer , Mark R Hutchinson , Linda R Watkins , Kirk W Johnson
DOI: 10.1517/13543784.16.7.935
关键词:
摘要: The treatment of neuropathic pain is a major unresolved medical challenge. Present pharmacotherapies only have modest efficacy and numerous side effects. use opioid analgesics additionally coupled with dependence withdrawal syndromes. Ibudilast (AV-411) non-selective phosphodiesterase inhibitor that also known to suppress glial cell activation. It has been used clinically for other indications good safety profile. As activation considered crucially contribute as well withdrawal, the authors conceived ibudilast may be useful treating these conditions. Preclinical data indicate crosses blood–brain barrier, tolerated, active on oral administration, reduces attenuates symptoms in diverse rat models pain. In addition, it enhances acute morphine analgesia tolerance withdrawal. Thus improve effic...